ChromaDex(US:CDXC)2025-11-04 22:30Financial Data and Key Metrics Changes - The company reported a record revenue of $34 million for Q3 2025, representing a 33% increase year over year, and a net income of $4.6 million compared to $1.9 million in the same period last year [5][14][17] - The cash position at the end of the quarter was $64.3 million with no debt [5][17] - Gross margin improved to 64.5%, up 100 basis points from 63.5% a year ago [16] Business Line Data and Key Metrics Changes - E-commerce business generated net sales of $19 million, a 29% increase year over year [5][14] - The distribution business saw a significant growth of 109% year over year, achieving $7 million in revenue [5][14] - Niagen ingredient business remained steady with revenue of $6.9 million, a 4% increase year over year [14] Market Data and Key Metrics Changes - The NAD market is expanding rapidly, with significant opportunities in skincare, cosmetics, food, beverage, and drug applications [8][10] - The company has onboarded over 1,000 wellness and healthcare clinics across the U.S. to offer the Niagen Plus product line [7][8] Company Strategy and Development Direction - The company aims to educate healthcare practitioners and consumers about Niagen as the most effective NAD booster available [6][8] - Plans to expand distribution of at-home injection kits via a telehealth platform are underway [7][34] - The company is considering establishing a standalone entity to pursue pharmaceutical applications of nicotinamide riboside, particularly for Parkinson's disease [42] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the updated full-year revenue growth guidance, revised from 22%-27% to 25%-30% year-over-year [18] - The company anticipates that gross margins will normalize on a quarterly basis moving forward, despite improvements year-over-year [16][19] - Management noted that the FDA's recent decision regarding NMN has not significantly impacted consumer purchasing behavior [36][37] Other Important Information - The company has over 40 peer-reviewed clinical studies supporting the efficacy of Niagen [9][12] - The National Advertising Division recently supported the company's position against false claims made by competitors regarding NAD products [10] Q&A Session Summary Question: What is the uptake looking like with the new partnership for IV? - Management indicated it is too early to provide feedback as the partnership just began reselling the material [24] Question: How does the "About NAD" site fit into the marketing funnel? - The site serves as an objective resource for information on NAD and is not part of the purchasing funnel [26] Question: Are at-home injection kits available in all clinics? - Currently, the kits are available in clinics, and the rollout for online purchasing is expected to take several months [33] Question: Has the FDA's announcement on NMN changed consumer purchasing behavior? - Management noted no significant changes in purchasing behavior since the announcement [36] Question: Will the company establish a standalone entity for pharmaceutical applications? - Management confirmed that establishing a standalone entity for pharmaceutical pursuits is likely, depending on study results and discussions with pharma companies [42]